Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells 75,608 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Ross Moat sold 75,608 shares of the firm’s stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $93.13, for a total transaction of $7,041,373.04. Following the completion of the transaction, the chief operating officer directly owned 10,294 shares of the company’s stock, valued at $958,680.22. This represents a 88.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ross Moat also recently made the following trade(s):

• On Monday, November 2nd, Ross Moat sold 27,977 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $92.36, for a total value of $2,583,955.72.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ KNSA traded up $2.49 during mid-day trading on Tuesday, hitting $93.29. The company had a trading volume of 1,021,631 shares, compared to its average volume of 705,858. The company has a market capitalization of $7.28 billion, a PE ratio of 71.76 and a beta of 0.04. The business’s 50-day simple moving average is $79.39 and its 200 day simple moving average is $60.29. Kiniksa Pharmaceuticals International, plc has a 1-year low of $37.02 and a 1-year high of $98.48.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its earnings results on Tuesday, October 27th. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. The firm had revenue of $285.97 million during the quarter, compared to analysts’ expectations of $260.66 million. On average, analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.26 EPS for the current year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several large investors have recently bought and sold shares of KNSA. Rubric Capital Management LP lifted its holdings in Kiniksa Pharmaceuticals International by 12.7% during the 1st quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock worth $180,562,000 after buying an additional 421,347 shares during the last quarter. Pictet Asset Management Holding SA boosted its position in shares of Kiniksa Pharmaceuticals International by 41.3% during the 3rd quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company’s stock worth $64,182,000 after acquiring an additional 251,578 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Kiniksa Pharmaceuticals International by 18.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 811,922 shares of the company’s stock valued at $39,086,000 after acquiring an additional 128,417 shares during the last quarter. Spruce Street Capital LP increased its holdings in shares of Kiniksa Pharmaceuticals International by 75.0% in the 1st quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock valued at $36,645,000 after acquiring an additional 326,081 shares during the last quarter. Finally, Bank of America Corp DE increased its holdings in shares of Kiniksa Pharmaceuticals International by 220.9% in the 1st quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock valued at $35,436,000 after acquiring an additional 506,576 shares during the last quarter. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Analysts Set New Price Targets

KNSA has been the subject of a number of analyst reports. The Goldman Sachs Group boosted their price objective on Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the stock a “buy” rating in a research report on Wednesday, October 28th. Weiss Ratings cut shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a report on Wednesday, October 28th. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. Canaccord Genuity Group boosted their price target on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Finally, Wedbush boosted their price target on shares of Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an “outperform” rating in a report on Wednesday, October 28th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $100.57.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.